Q-omics provides the consensus-scored SPATA9 profile across patient tissues and cancer cell-line models. SPATA9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPATA9 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SPATA9 RNA expression shows 17,744 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where SPATA9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA9 survival associations across molecular data types. SPATA9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA9 RNA expression–survival associations across cancer types. High SPATA9 expression shows unfavorable associations in KIRC, KIRP and UVM, but favorable associations in LAML, THCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPATA9 RNA expression.
This table summarizes SPATA9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPATA9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA9 shows lower tumor expression in BRCA, KICH, UCEC and PAAD and higher tumor expression in THCA and LUAD. The THCA box plot shows higher SPATA9 RNA expression in tumor versus normal tissue (log2 FC = +0.709, t-test p < 0.001).
This table shows molecular features associated with SPATA9 in patient tissues and cancer cell lines. In patient samples, SPATA9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
